Mitropoulos K A
MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, St. Bartholomew's and the Royal London School of Medicine and Dentistry, University of London, United Kingdom.
Thromb Res. 1999 Apr 15;94(2):117-29. doi: 10.1016/s0049-3848(98)00207-2.
The incubation of normal human plasma in the presence of sulphatide vesicles results in the generation of amidolytic activity due to factor XIIa (FXIIa) and to kallikrein (KRN). The progress of the generation of the enzymes distinguished a high initial rate of enzyme generation, a decline of this rate to maximum amidolytic activity ([FXIIa]m and [KRN]m) and a negative pseudo-first-order rate attributed to enzyme inactivation by plasma C1-inhibitor (C1INH). [FXIIa]m and [KRN]m were determined after the treatment of various dilutions of plasma in the presence of 4, 15, or 40 microM sulphatide vesicles. At all levels of sulphatides, [FXIIa]m and [KRN]m initially increased with the concentration of plasma, to reach a plateau at higher concentration of plasma. The plateau activities of the generated enzymes and the optimal concentration of plasma both increased with the level of sulphatide vesicles. The pseudo-first-order inactivation rate for KRN increased progressively with the concentration of plasma but the respective rate for FXIIa was independent of the plasma concentration. The data suggest that contiguous binding of plasma FXIIa, factor XII (FXII), and the complexes of high molecular weight kininogen (HK) with prekallikrein (HK-PKRN) and factor XI (HK-FXI) to an electronegative surface induces a rapid generation of FXIIa and KRN. The concentration of the electronegative surface controls the levels of generated FXIIa and KRN and their release to the bulk phase. The released FXIIa and KRN are both inactivated by C1INH.
在硫苷脂囊泡存在的情况下,正常人血浆的孵育会由于因子XIIa(FXIIa)和激肽释放酶(KRN)而产生酰胺水解活性。酶生成过程的进展表现为酶生成的初始速率较高,该速率下降至最大酰胺水解活性([FXIIa]m和[KRN]m),以及由于血浆C1抑制剂(C1INH)使酶失活而导致的负假一级反应速率。在4、15或40微摩尔硫苷脂囊泡存在的情况下,对不同稀释度的血浆进行处理后,测定了[FXIIa]m和[KRN]m。在所有硫苷脂水平下,[FXIIa]m和[KRN]m最初都随血浆浓度增加,在较高血浆浓度时达到平稳状态。生成酶的平稳活性和血浆的最佳浓度均随硫苷脂囊泡水平的增加而增加。KRN的假一级失活速率随血浆浓度逐渐增加,但FXIIa的相应速率与血浆浓度无关。数据表明,血浆FXIIa、因子XII(FXII)以及高分子量激肽原(HK)与前激肽释放酶(HK-PKRN)和因子XI(HK-FXI)的复合物与带负电表面的连续结合会快速生成FXIIa和KRN。带负电表面的浓度控制着生成的FXIIa和KRN的水平及其向本体相的释放。释放的FXIIa和KRN均被C1INH失活。